Latest News on HRTX

Financial News Based On Company


Advertisement
Advertisement

CorMedix Therapeutics to Acquire Substantially All Assets of Heron Therapeutics, Expanding Its Portfolio of Products Used in Institutional Settings of Care

https://biobuzz.io/news/cormedix-therapeutics-to-acquire-substantially-all-assets-of-heron-therapeutics-expanding-its-2/
CorMedix Therapeutics announced it will acquire substantially all assets of Heron Therapeutics for $145 million in cash, 14,833,333 shares of CorMedix common stock, and up to $55 million in earn-out payments and royalties. This acquisition adds four commercial-stage products, including ZYNRELEF for postoperative pain, to CorMedix's portfolio, leveraging its existing institutional commercial infrastructure and aiming for $45-$60 million in operating cost synergies. The transaction, expected to close in Q1 2027, will be immediately accretive to CorMedix's earnings and free cash flow, and Heron will remain a publicly traded company, retaining tax attributes and exploring new strategic opportunities.

Heron Therapeutics, Inc. (HRTX) Seasonal Returns Chart - Yahoo Finance

https://ca.finance.yahoo.com/quote/HRTX/seasonality/
This article provides a seasonal returns chart for Heron Therapeutics, Inc. (HRTX), showing the average monthly price return from 2016 to 2026. The stock's current real-time price on NasdaqCM is also displayed, along with pre-market information.

Form 4 Heron Therapeutics Inc: Mark Earl Hensley (COO) For: 6 November

https://ca.investing.com/news/stock-market-news/form-4-heron-therapeutics-inc-mark-earl-hensley-coo-for-6-november-93CH-4950722
This article reports on a Form 4 filing for Heron Therapeutics Inc., specifically noting a transaction involving Mark Earl Hensley, the Chief Operating Officer, on November 6th. The filing indicates insider trading activity for the company.

CorMedix Announces $145M Cash and Stock Deal to Acquire Heron Therapeutics Assets

https://kalkinemedia.com/us/news/announcements/cormedix-announces-145m-cash-and-stock-deal-to-acquire-heron-therapeutics-assets
CorMedix Inc. has announced an Asset Purchase Agreement to acquire substantially all assets of Heron Therapeutics, Inc. for $145 million in cash, 14,583,333 shares of its common stock, and contingent royalty and earn-out payments. The deal, approved by CorMedix's board, includes performance-based payments tied to future sales of Heron's products like ZYNRELEF, CINVANTI, and SUSTOL, along with non-compete and non-solicitation covenants.

CorMedix to acquire Heron Therapeutics for $145M in cash upfront

https://www.tipranks.com/news/the-fly/cormedix-to-acquire-heron-therapeutics-for-145m-in-cash-upfront-thefly-news
CorMedix (CRMD) has announced an agreement to acquire substantially all assets of Heron Therapeutics (HRTX) for $145 million in cash upfront, 14,583,333 shares of CorMedix common stock, and up to $55 million in contingent earn-out payments and royalties. The deal, valued at approximately $222.6 million upfront, has been unanimously approved by both companies' boards and is expected to close in the first quarter of 2027. It also includes the assumption of Heron's multi-product development and license agreement rights, with certain Heron stockholders agreeing to vote in favor of the transaction.
Advertisement

CorMedix to Buy Heron Therapeutics Assets for $222.6M, Adding Four Hospital Drugs

https://finance.biggo.com/news/61799080-93c5-4786-9e9d-0ecd7c08db78
CorMedix Inc. announced an agreement to acquire substantially all assets of Heron Therapeutics Inc. for approximately $222.6 million, consisting of $145 million in cash and 14,583,333 shares. This acquisition will add four commercial products—ZYNRELEF, APONVIE, CINVANTI, and SUSTOL—to CorMedix's hospital and acute-care portfolio. The deal, which aims for $45 million to $60 million in annual cost synergies by late 2027 and projects pro forma 2026 revenue of $465 million to $490 million, is expected to close in the first quarter of 2027.

Heron Therapeutics earnings missed by $0.02, revenue fell short of estimates

https://www.investing.com/news/earnings/heron-therapeutics-earnings-missed-by-002-revenue-fell-short-of-estimates-5012264
Heron Therapeutics (NASDAQ: HRTX) reported a third-quarter EPS of $-0.030, missing analyst estimates by $0.02, and revenue of $35.3 million, which fell short of the $41.95 million consensus estimate. The company's stock price closed at $0.29, marking a significant decline over the past year. InvestingPro rates Heron Therapeutics' financial health as "fair performance."

CorMedix Announces Agreement to Acquire Heron Therapeutics Assets

https://www.tipranks.com/news/company-announcements/cormedix-announces-agreement-to-acquire-heron-therapeutics-assets
CorMedix has agreed to acquire substantially all of Heron Therapeutics' assets for $145 million in cash, 14,583,333 CorMedix shares, royalties, and potential earn-outs up to $55 million. The acquisition will expand CorMedix's presence in acute care and oncology supportive care with four commercial-stage products. The transaction is subject to Heron stockholder approval, antitrust clearance, and other customary conditions, with a $150 million senior secured loan agreement in place to help fund the deal.

Form 8K Heron Therapeutics Inc For: 9 November By Investing.com

https://uk.investing.com/news/stock-market-news/form-8k-heron-therapeutics-inc-for-9-november-93CH-4968429
This article announces that Heron Therapeutics Inc. filed a Form 8K on November 9, 2026. The filing is a standard disclosure document for significant events that shareholders should know about. The article itself provides no further details about the content of the Form 8K.

HRTX: SEC Form 10-Q filed by Heron Therapeutics Inc.

https://www.quantisnow.com/insight/sec-form-10-q-filed-by-heron-therapeutics-inc-6780562
Heron Therapeutics (HRTX) filed its quarterly report for Q3 2026, revealing $23.4 million in cash, cash equivalents, and short-term investments as of September 30, 2026. The company expressed substantial doubt about its ability to continue as a going concern without additional funding or an asset sale, despite management's belief that current cash will fund operations for at least one year. The filing also highlighted covenant risks associated with its Working Capital Facility Agreement and referenced a private placement equity offering.
Advertisement

Heron Therapeutics Announces Third Quarter 2026 Financial Results

https://www.globenewswire.com/news-release/2026/11/09/3398417/0/en/heron-therapeutics-announces-third-quarter-2026-financial-results.html
Heron Therapeutics reported its third-quarter 2026 financial results, with total net revenue of $35.3 million. The company announced a definitive agreement for CorMedix Therapeutics to acquire substantially all of Heron's assets. Key products ZYNRELEF® and APONVIE® showed significant net revenue increases compared to Q3 2025.

Form 4 Heron Therapeutics Inc: Mark Earl Hensley (COO) For: 30 October

https://ca.investing.com/news/stock-market-news/form-4-heron-therapeutics-inc-mark-earl-hensley-coo-for-30-october-93CH-4926601
This article reports on a Form 4 filing for Heron Therapeutics Inc., detailing insider transaction information for Mark Earl Hensley, the Chief Operating Officer. The filing pertains to activity on October 30.

Form 4 Heron Therapeutics Inc: Mark Earl Hensley (COO) For: 30 October

https://uk.investing.com/news/stock-market-news/form-4-heron-therapeutics-inc-mark-earl-hensley-coo-for-30-october-93CH-4953620
This article reports on a Form 4 filing for Heron Therapeutics Inc., specifically detailing a transaction related to its COO, Mark Earl Hensley, on October 30. The filing indicates insider activity for the pharmaceutical company, which is identified by its stock symbol HRTX.

Heron Therapeutics stock heads toward November 9 results

https://www.ad-hoc-news.de/boerse/news/corporate-news/heron-therapeutics-stock-heads-toward-november-9-results/70436657
Heron Therapeutics (HRTX) is scheduled to report its third-quarter 2026 financial results and discuss recent business highlights on November 9, with an investor call and webcast at 8:30 a.m. Eastern Time. The biotechnology company focuses on therapeutic innovations for acute-care and oncology patients. As of October 30, 2026, the stock traded at 0.25 euros on Lang & Schwarz.

Heron Therapeutics (HRTX) Expected to Release Earnings on Tuesday

https://www.marketbeat.com/instant-alerts/upcoming-heron-therapeutics-hrtx-expected-to-release-earnings-on-tuesday-2026-10-27/
Heron Therapeutics (HRTX) is expected to announce its Q3 2026 financial results before market open on Tuesday, November 3rd, with analysts forecasting a loss of $0.03 per share on $37.50 million in revenue. The biotechnology company continues to face financial challenges, marked by negative net margins and returns on equity, and its stock is currently trading near its 52-week low. Analyst sentiment for HRTX is generally "Hold" with an average price target of $2.00.
Advertisement

Heron Therapeutics to Report Third Quarter 2026 Financial Results on Monday, November 9, 2026

https://finance.yahoo.com/healthcare/articles/heron-therapeutics-report-third-quarter-000900349.html
Heron Therapeutics, Inc. (Nasdaq: HRTX) announced it will host a conference call and live webcast on Monday, November 9, 2026, at 8:30 a.m. ET to report its third-quarter financial results and discuss recent business highlights. The commercial-stage biotechnology company focuses on developing and commercializing therapeutic innovations for acute care and oncology patients.

Heron Therapeutics to Report Third Quarter 2026 Financial Results on November 9, 2026

https://www.quiverquant.com/news/Heron+Therapeutics+to+Report+Third+Quarter+2026+Financial+Results+on+November+9%2C+2026
Heron Therapeutics, Inc. announced it will host a conference call and live webcast on November 9, 2026, at 8:30 a.m. ET to discuss its third quarter financial results and recent business developments. The company is a commercial-stage biotechnology firm focused on improving patient care for acute and oncology patients. They also cautioned that the press release contains forward-looking statements subject to risks and uncertainties.

Heron Therapeutics to Report Third Quarter 2026 Financial Results on Monday, November 9, 2026

https://www.globenewswire.com/news-release/2026/10/27/3388655/0/en/heron-therapeutics-to-report-third-quarter-2026-financial-results-on-monday-november-9-2026.html
Heron Therapeutics, Inc. announced that it will host a conference call and live webcast on Monday, November 9, 2026, at 8:30 a.m. ET to report its third quarter financial results and discuss recent business highlights. Interested parties can access the call via a registration link for dial-in details or through the Investor Relations section of Heron's website. An archive of the teleconference will be available on their website for 60 days.

Heron sets November 3 results: Heron Therapeutics stock closed USD 0.30 on October 23, 2026

https://www.ad-hoc-news.de/boerse/news/corporate-news/heron-sets-november-3-results-heron-therapeutics-stock-closed-usd-0-30-on-october-23-2026/70405886
Heron Therapeutics (HRTX) is scheduled to report its third-quarter 2026 financial results on November 3, 2026. The company's stock closed at USD 0.30 on October 23, 2026, on Nasdaq. Analysts currently hold a neutral consensus with an average 12-month price target of USD 2.00, significantly above the current trading price.

Heron Therapeutics, Inc. Estimates – NASDAQ:HRTX

https://www.tradingview.com/symbols/NASDAQ-HRTX/financials-estimates/
This article provides an overview of Heron Therapeutics, Inc. (NASDAQ: HRTX) financials and analyst estimates available on TradingView. It directs users to explore reported financial data and analyst estimates across various statements and valuation metrics. The platform allows comparison of actual results with average, high, and low estimates, and visualization of trends over time for both annual and quarterly data.
Advertisement

Heron Therapeutics Inc Estimates – BX:AXD2

https://www.tradingview.com/symbols/BX-AXD2/financials-estimates/
This article provides an overview of Heron Therapeutics Inc. (AXD2 on BX Swiss) financials, focusing on actual reported financial data and analyst estimates. Users can explore income statements, balance sheets, cash flow statements, and valuation metrics, comparing actual results with average, high, and low estimates. The platform also allows visualization of trends over time for both annual and quarterly data.

Form 4 Heron Therapeutics Inc: Ira Duarte (EVP, Chief Financial Officer) For: 19 October

https://ng.investing.com/news/stock-market-news/form-4-heron-therapeutics-inc-ira-duarte-evp-chief-financial-officer-for-19-october-93CH-2749250
This article reports on a Form 4 filing for Heron Therapeutics Inc., indicating a transaction by Ira Duarte, the EVP and Chief Financial Officer, on October 19. Form 4 filings are regulatory documents disclosing changes in beneficial ownership of securities by company insiders. The article highlights the company's stock symbol HRTX, which saw a 4.72% increase.

Form 4 Heron Therapeutics Inc: Craig A. Collard (Director, CEO) For: 19 October

https://ng.investing.com/news/stock-market-news/form-4-heron-therapeutics-inc-craig-a-collard-director-ceo-for-19-october-93CH-2749249
This article reports on a Form 4 filing for Heron Therapeutics Inc., indicating a transaction involving Craig A. Collard, who serves as both a Director and CEO of the company. The filing pertains to activity on October 19 and was published on October 21, 2026. The stock symbol HRTX is noted with a significant drop of 14.96%.

Quarterly stock vesting gives Heron Therapeutics (HRTX) development chief 3,874 shares.

https://www.stocktitan.net/sec-filings/HRTX/form-4-heron-therapeutics-inc-de-insider-trading-activity-373269078414.html
William P. Forbes, EVP and Chief Development Officer at Heron Therapeutics, converted 3,874 restricted stock units into common shares on October 19, 2026. These units vest in 16 equal quarterly installments starting one quarter after the January 19, 2024 grant date. Forbes also had 1,102 common shares withheld for tax liability at $0.36 per share, and now holds 19,372 restricted stock units and 243,945 common shares.

Heron Therapeutics CEO Craig Collard Converts 13,797 RSUs, Withholds 3,360 Shares for Taxes on Oct 19, 2026

https://kalkinemedia.com/us/news/announcements/heron-therapeutics-ceo-craig-collard-converts-13797-rsus-withholds-3360-shares-for-taxes-on-oct-19-2026
Craig A. Collard, CEO and Director of Heron Therapeutics, Inc., converted 13,797 restricted stock units (RSUs) into common stock and withheld 3,360 shares for tax obligations on October 19, 2026. Following these transactions, Collard directly holds 866,929 shares of common stock, with 68,984 RSUs remaining beneficially owned. The RSUs vest in 16 equal quarterly installments starting one quarter after the January 19, 2024 grant date.
Advertisement

Stock awards convert into 13,797 shares for Heron Therapeutics (HRTX) CEO Craig A. Collard.

https://www.stocktitan.net/sec-filings/HRTX/form-4-heron-therapeutics-inc-de-insider-trading-activity-4e8028eec882.html
Heron Therapeutics CEO Craig A. Collard acquired 13,797 shares of common stock through the exercise/conversion of restricted stock units on October 19, 2026. The restricted stock units vest in 16 equal quarterly installments, beginning one quarter after the January 19, 2024, grant date. Following the transaction, Collard's direct holdings include 68,984 restricted stock units and 866,929 common shares.

MarketBeat estimates November 3 results for Heron Therapeutics stock

https://www.ad-hoc-news.de/boerse/news/nebenwerte/marketbeat-estimates-november-3-results-for-heron-therapeutics-stock/70376916
MarketBeat estimates that Heron Therapeutics (HRTX) will report its third-quarter 2026 results on November 3, 2026, before market open, with an expected revenue of USD 37.50 million and a loss of USD 0.03 per share. The company's six-month revenue for 2026 was down 4.90 percent compared to 2025, primarily due to a decline in oncology revenue despite growth in acute-care revenue. HRTX stock is currently trading significantly below its 52-week high, with the upcoming earnings report expected to test the balance between acute-care growth and oncology pressure.

Heron Therapeutics stock at EUR 0.34 as Nasdaq move reaches 4.4 percent

https://www.ad-hoc-news.de/boerse/news/nebenwerte/heron-therapeutics-stock-at-eur-0-34-as-nasdaq-move-reaches-4-4-percent/70332753
Heron Therapeutics stock traded at EUR 0.34 on October 15, 2026, marking a 4.4 percent increase on Nasdaq. The company reported Q2 2026 net product sales of USD 37.70 million and a net loss of USD 5.50 million. Investors are anticipating the third-quarter 2026 results, expected on November 3, 2026.

Heron Therapeutics stock gained 15.86 percent to USD 0.38

https://www.ad-hoc-news.de/boerse/news/nebenwerte/heron-therapeutics-stock-gained-15-86-percent-to-usd-0-38/70261413
Heron Therapeutics (HRTX) stock saw a 15.86% gain, closing at $0.38 on October 7, 2026, with significant trading volume. The company reported Q2 2026 revenue of $37.7 million, an increase from previous quarters, and announced a new licensing deal with Long Grove Pharmaceuticals. Investors are looking forward to the Q3 2026 earnings report scheduled for November 3, 2026.

Heron Therapeutics Q3 2026 Earnings Date and Estimates

https://www.marketbeat.com/earnings/reports/2026-11-3-heron-therapeutics-inc-stock/
Heron Therapeutics (HRTX) is scheduled to report its Q3 2026 earnings on Tuesday, November 3, 2026, before market open, with a conference call at 8:30 AM ET. Analysts project a loss of -$0.03 per share on revenue of $37.50 million. The company missed consensus EPS estimates in its last reported quarter.
Advertisement

Heron Therapeutics stock faces a guidance reset after Q2 loss

https://www.ad-hoc-news.de/boerse/news/nebenwerte/heron-therapeutics-stock-faces-a-guidance-reset-after-q2-loss/70250888
Heron Therapeutics (HRTX) stock is facing a guidance reset after reporting a Q2 2026 net loss of $5.5 million on sales of $37.7 million, missing analyst expectations. The company also withdrew its full-year 2026 guidance due to patent uncertainty and strategic alternatives. Despite a new licensing agreement for product expansion, analysts maintain a "Hold" consensus on the stock, which was trading at $0.34, significantly below its $2.00 average 12-month price target.

Heron Therapeutics stock fell 2.33 percent on October 2

https://www.ad-hoc-news.de/boerse/news/corporate-news/heron-therapeutics-stock-fell-2-33-percent-on-october-2/70231933
Heron Therapeutics stock declined by 2.33% to USD 0.35 on Nasdaq on October 2, 2026, after reporting Q2 revenue of USD 37.67 million, missing the expected USD 42.19 million. The company recently secured a 10-year exclusive license agreement with Long Grove Pharmaceuticals and Capstone to expand its commercial portfolio in the US. Despite a consensus Hold rating and an average analyst target price of USD 2.00, the stock remains in micro-cap territory with a market capitalization of USD 65.8 million.

Heron Therapeutics Expands U.S. Portfolio Through Licensing Deal

https://www.theglobeandmail.com/investing/markets/markets-news/Tipranks/4890994/heron-therapeutics-expands-u-s-portfolio-through-licensing-deal/
Heron Therapeutics has expanded its U.S. portfolio by entering into a multi-product Development and License Agreement with Long Grove Pharmaceuticals and Capstone Development Services. This 10-year agreement grants Heron exclusive U.S. rights to import, distribute, sell, and market specific Long Grove products, along with a non-exclusive worldwide manufacturing license for U.S. sales. An analyst has issued a Buy rating on HRTX stock with a $2.00 price target, while TipRanks' AI Analyst, Spark, rates HRTX as Neutral due to financial profile and technical weaknesses.

Heron Therapeutics signs multi-product license agreement with Long Grove By Investing.com

https://ng.investing.com/news/stock-market-news/heron-therapeutics-signs-multiproduct-license-agreement-with-long-grove-93CH-2714883
Heron Therapeutics (NASDAQ:HRTX) has entered into a multi-product development and license agreement with Long Grove Pharmaceuticals and Capstone Development Services. This agreement grants Heron Therapeutics exclusive rights to import, distribute, sell, and market certain products in the US, along with a non-exclusive manufacturing license worldwide for sale in the designated territory. Despite the stock appearing undervalued by InvestingPro, the company faces challenges including quickly burning through cash and significant debt, as highlighted by InvestingPro Tips.

Form 8K Heron Therapeutics Inc For: 29 September By Investing.com

https://ng.investing.com/news/stock-market-news/form-8k-heron-therapeutics-inc-for-29-september-93CH-2714858
This article announces that Heron Therapeutics Inc. filed a Form 8K for September 29. It is a brief, standard news item regarding a regulatory filing by the company, published by Investing.com. The filing itself is not detailed in the article.
Advertisement

Form 8K Heron Therapeutics Inc For: 29 September By Investing.com

https://za.investing.com/news/stock-market-news/form-8k-heron-therapeutics-inc-for-29-september-93CH-4483314
This article reports that Heron Therapeutics Inc. filed a Form 8K on September 29, 2026. The filing is a standard disclosure for public companies and is available through Investing.com. Heron Therapeutics stock symbol HRTX showed a 2.61% increase.

Heron Therapeutics signs multi-product license agreement with Long Grove

https://www.investing.com/news/sec-filings/heron-therapeutics-signs-multiproduct-license-agreement-with-long-grove-93CH-4923662
Heron Therapeutics has signed a multi-product development and license agreement with Long Grove Pharmaceuticals, LLC and Capstone Development Services Company, LLC. This agreement grants Heron Therapeutics exclusive rights to import, distribute, sell, and market certain products in the US and its territories, along with non-exclusive manufacturing rights globally for sale in the designated region. The deal involves regulatory, sales, and royalty payments to Long Grove, and comes as Heron Therapeutics, despite a recent stock decline, is identified as undervalued by InvestingPro.

Heron Therapeutics, Inc. (NASDAQ:HRTX) Stock Has Consensus Target Price of $2.00

https://www.marketbeat.com/instant-alerts/consensus-heron-therapeutics-inc-nasdaq-hrtx-stock-has-consensus-target-price-of-200-2026-09-25/
Heron Therapeutics (NASDAQ:HRTX) has a consensus "Hold" rating from analysts, with an average 12-month price target of $2.00. The company recently reported a quarterly loss of $0.03 per share and revenue below analyst expectations, and its shares opened at $0.29, significantly below its 52-week high. Institutional investors hold a substantial 80.01% of the stock, with some firms increasing their positions.

Heron Therapeutics stock awaits its next reported figures

https://www.ad-hoc-news.de/boerse/news/nebenwerte/heron-therapeutics-stock-awaits-its-next-reported-figures/70150077
Heron Therapeutics' stock entered September 22, 2026, without an updated market quote, making its previous reported figures the current reference. The article highlights the lack of new revenue, earnings, or guidance figures, and an unsubstantiated future reporting date or company catalyst. Investors will need to await the next verified company disclosure for updated comparisons.

Heron Therapeutics (AXD2) Q4 2025 Earnings Report - Results, Call & Slides

https://www.tipranks.com/stocks/ch:axd2/earnings/q4-2025-report
Heron Therapeutics (AXD2) announced its Q4 2025 earnings, reporting actual EPS of -CHF0.02, which met consensus expectations. The company's actual revenue of CHF32.87M beat the expected CHF32.29M. Heron Therapeutics also provided details for its upcoming earnings reports, with the next one estimated for November 10, 2026.
Advertisement

Heron Therapeutics Sees Unusually High Options Volume (NASDAQ:HRTX)

https://www.marketbeat.com/instant-alerts/options-heron-therapeutics-sees-unusually-high-options-volume-nasdaq-hrtx-2026-09-16/
Heron Therapeutics (NASDAQ:HRTX) recently experienced an unusual surge in bearish options trading, with put options volume increasing by approximately 22,951% compared to its typical levels. This comes as the stock trades near its 12-month low and after missing revenue expectations, despite institutional investors holding about 80.01% of the shares. Analysts currently maintain a consensus "Hold" rating with an average price target of $2.00 for HRTX.

10,550,750 Shares in Heron Therapeutics, Inc. $HRTX Bought by BlackRock Inc.

https://www.marketbeat.com/instant-alerts/filing-10550750-shares-in-heron-therapeutics-inc-hrtx-bought-by-blackrock-inc-2026-09-06/
BlackRock Inc. has acquired over 10.55 million shares of Heron Therapeutics (NASDAQ:HRTX) in the second quarter, representing a 5.57% stake valued at approximately $4.5 million. Despite this significant institutional investment, which brings total institutional ownership to 80.01%, analysts maintain a cautious "Hold" consensus rating with an average price target of $2.00. The biotechnology company reported a quarterly loss of $0.03 per share and revenue below analyst estimates, with its stock currently trading near its 52-week low.

Tejara Capital Ltd Buys New Stake in Heron Therapeutics, Inc. $HRTX

https://www.marketbeat.com/instant-alerts/filing-tejara-capital-ltd-buys-new-stake-in-heron-therapeutics-inc-hrtx-2026-08-21/
Tejara Capital Ltd has acquired a new stake in Heron Therapeutics, Inc. (NASDAQ:HRTX) during the second quarter, purchasing over 6.51 million shares valued at approximately $2.78 million, making it their 28th largest position. Other institutional investors also modified their holdings, with institutional ownership reaching 80.01%. Heron Therapeutics shares opened at $0.31, near a one-year low, after reporting a quarterly loss of $0.03 per share and revenue below analyst estimates, leading to a consensus "Hold" rating and an average price target of $2.00 from analysts.

H.C. Wainwright Maintains Heron Therapeutics(HRTX.US) With Hold Rating

https://www.moomoo.com/news/post/74853575/hc-wainwright-maintains-heron-therapeutics-hrtxus-with-hold-rating
H.C. Wainwright has reiterated its Hold rating for Heron Therapeutics (HRTX.US). The article does not provide further details on the reasons for this rating or any financial analysis.

Weekly Recap: Guidance withdrawn over CINVANTI patent and HRTX Q2 revenue $37.7M

https://www.tradingview.com/news/tradingview:c442012b5d5e4:0-weekly-recap-guidance-withdrawn-over-cinvanti-patent-and-hrtx-q2-revenue-37-7m/
Heron Therapeutics Inc (HRTX) has withdrawn its 2026 sales and Adjusted EBITDA guidance due to uncertainty surrounding the CINVANTI patent and an ongoing strategic review. The company reported Q2 revenue of $37.7M, including $11.1M from ZYNRELEF and $4.2M from APONVIE, with a cash balance of $42.7M. This decision follows their financial performance snapshot for Q2 2026.
Advertisement

HERON THERAPEUTICS INC : H.C. WAINWRIGHT CUTS TO NEUTRAL FROM BUY

https://www.webull.com/news/15383635048932352
H.C. Wainwright has downgraded Heron Therapeutics Inc. from a "Buy" rating to "Neutral." This change in analyst rating indicates a revised outlook on the company's stock performance. The article, sourced from Reuters, reports on this significant financial action.

H.C. Wainwright Downgrades Heron Therapeutics(HRTX.US) to Hold Rating

https://www.moomoo.com/news/post/74485323/hc-wainwright-downgrades-heron-therapeutics-hrtxus-to-hold-rating
H.C. Wainwright has downgraded Heron Therapeutics (HRTX.US) from a Buy to a Hold rating. This change in rating reflects a revised outlook from the firm regarding the pharmaceutical company.

Heron Therapeutics Inc (HRTX) (Q2 2026) Earnings Call Highlights: Revenue Growth Amid Strategic ...

https://uk.finance.yahoo.com/news/heron-therapeutics-inc-hrtx-q2-210141589.html
Heron Therapeutics reported Q2 2026 net revenue of $37.7 million, an increase from both the previous quarter and the prior year, driven by strong growth in ZYNRELEF and APONVIE sales, and improved Adjusted EBITDA. However, net revenue fell short of expectations due to slower growth in CINVANTI and ZYNRELEF, competitive pressures, and a negative court decision regarding CINVANTI patents, leading to the withdrawal of full-year guidance. The company amended its credit facility and is exploring strategic alternatives amidst market uncertainties.

Heron Therapeutics Q2 Earnings Call Highlights

https://www.marketbeat.com/instant-alerts/heron-therapeutics-q2-earnings-call-highlights-2026-08-10/
Heron Therapeutics reported second-quarter net revenue of $37.7 million, exceeding prior-year figures but falling short of management expectations for key products. Sales of ZYNRELEF and APONVIE grew, while CINVANTI sales declined due to branded competition and increased generic risk following a Delaware court ruling. The company has appealed the decision, withdrawn its 2026 financial guidance, paused salesforce expansion, and is evaluating strategic alternatives while making debt payments under an amended credit facility.

Heron Therapeutics Q2 2026 Loss Widens 50.0% Beyond Estimates

https://news.alphastreet.com/heron-therapeutics-q2-2026-loss-widens-50-0-beyond-estimates/amp/
Heron Therapeutics (NASDAQ: HRTX) reported a Q2 2026 diluted loss of $0.03 per share, exceeding analyst estimates by 50.0%, and revenue of $37.7 million, which fell 10.7% short of expectations. The company experienced a 1.6% stock drop as its largest segment, Oncology, saw a 15.9% year-over-year revenue decline, raising concerns despite a generally bullish analyst sentiment. Investors are advised to monitor the company's efforts to narrow losses and boost revenue growth.
Advertisement
Advertisement
Advertisement
Advertisement

Sign Up free to view live trades and discussion forum to make more informed financial decisions. No credit card is required for sign up!
View Daily Trades
Join Discussion

Advertisement
Advertisement
Advertisement
Advertisement